Treatment with PLT3 for 7 days led to significant improvement in glucose intolerance (Supplementary Fig. 8b,c), hyperinsulinemia (Supplementary Fig. 8d), hepatic steatosis (Supplementary Fig. 8e), accompanied by an elevation in circulating adiponectin (Supplementary Fig. 8f), whereas treatment with LT3 and FT3 had no obvious effect (Supplementary Fig. 8b–f) suggesting that the metabolic benefits of PLT3 are not merely attributed to the reduction in obesity. The gene discussed is ADIPOQ; the disease is Glucose intolerance.